UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 11, 2015
ZOSANO PHARMA CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-36570 |
|
45-4488360 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
34790 Ardentech Court
Fremont, CA 94555
(Address of principal executive offices) (Zip Code)
(510) 745-1200
Registrants telephone number, including area code
Not applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 |
Results of Operations and Financial Condition. |
On May 11, 2015, Zosano Pharma
Corporation issued a press release titled Zosano Pharma Reports First Quarter 2015 Financial Results. The press release is furnished herewith as Exhibit 99.1.
Item 9.01 |
Financial Statements and Exhibits. |
|
|
|
Exhibit |
|
Description |
|
|
99.1 |
|
Press release dated May 11, 2015, titled Zosano Pharma Reports First Quarter 2015 Financial Results |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ZOSANO PHARMA CORPORATION |
|
|
|
|
Dated: May 11, 2015 |
|
|
|
By: |
|
/s/ Vikram Lamba |
|
|
|
|
|
|
Name: Vikram Lamba |
|
|
|
|
|
|
Title: President and Chief Executive Officer |
3
EXHIBIT INDEX
|
|
|
Exhibit |
|
Description |
|
|
99.1 |
|
Press release dated May 11, 2015, titled Zosano Pharma Reports First Quarter 2015 Financial Results |
4
Exhibit 99.1
FOR IMMEDIATE RELEASE
Zosano Pharma Reports First Quarter 2015 Financial Results
FREMONT, CA, May 11, 2015 Zosano Pharma Corporation (NASDAQ: ZSAN), a clinical-stage specialty pharmaceutical company that has developed a
proprietary transdermal microneedle patch system to deliver drug formulations through the skin for the treatment of a variety of indications, today announced financial results for the three months ended March 31, 2015.
The first quarter of 2015 was a significant period of progress for Zosano Pharma, especially with the completion of our initial public offering, our
listing on the NASDAQ, and the concurrent private placement with Eli Lilly in January, said Vikram Lamba, Zosanos President and Chief Executive Officer. We remain focused on execution across our entire portfolio, including
preparing for Phase 3 development of Daily ZP-PTH in osteoporosis and completing a Phase 2 hypoglycemia study of ZP-Glucagon in the coming months.
Upcoming Clinical Development Milestones
Daily ZP-PTH
for osteoporosis
|
|
|
Confirm Phase 3 clinical trial design with regulatory authorities expected by YE 2015 |
|
|
|
Establish Phase 3 clinical supply inventory expected in Q4 2015 |
ZP-Glucagon for hypoglycemia
|
|
|
Complete Phase 2 clinical trial in diabetic patients with induced hypoglycemia expected in Q3 2015 |
ZP-Triptan for migraine
|
|
|
Complete Phase 1 clinical trial expected by YE 2015 |
Financial Results for the Quarter Ended
March 31, 2015
|
|
|
Zosano reported a net loss for the first quarter of 2015 of $4.6 million, or $0.47 per share on a basic and diluted basis, compared with a net loss of $2.4 million, or $0.46 per share on a basic and diluted basis, for
the first quarter of 2014. |
|
|
|
Total revenue for the first quarter of 2015 was $0.2 million, compared with $1.6 million in the first quarter of 2014. The decrease was primarily due to the non-recurrence in 2015 of license revenue earned in 2014, as a
result of the termination of the companys license agreement with Asahi Kasei Pharma. |
|
|
|
Research and development (R&D) expenses for the first quarter of 2015 were $3.1 million, compared with $2.9 million in the first quarter of 2014. The increase was primarily due to the commencement of the
companys Phase 2 clinical trial of its ZP-Glucagon product candidate in Australia. |
|
|
|
General and administrative (G&A) expenses for the first quarter of 2015 were $1.3 million, compared with $1.2 million in the first quarter of 2014. The increase was primarily due to increased administrative expenses
associated with being a public company. |
|
|
|
As of March 31, 2015, Zosano had cash and cash equivalents of $55.9 million compared to $1.2 million as of December 31, 2014. Total debt as of March 31, 2015 was $14.7 million, compared to $22.1 million
at the end of 2014. |
Financial Guidance
Management expects Zosanos cash and marketable securities to be sufficient to fund ongoing operations through mid-2016. This projection does not assume
the receipt of any milestone payments from existing partners nor any funds from new financings or partnerships.
About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company that has developed a proprietary transdermal microneedle patch system to deliver
drug formulations through the skin for the treatment of a variety of indications. Zosanos microneedle patch system offers rapid onset, consistent drug delivery, improved ease of use and room-temperature stability, benefits that the company
believes often are unavailable using oral formulations or injections. Zosanos microneedle patch system has the potential to deliver numerous medications for a wide variety of indications in commercially attractive markets. It has been tested
in more than 400 patients with over 30,000 patches successfully applied to humans in Phase 1 and Phase 2 clinical studies. Learn more at www.zosanopharma.com.
Forward-Looking Statements
This press release
contains forward-looking statements regarding the timing of expected clinical development milestones, sufficiency of Zosano Pharmas capital resources and need for future funding and other future events and expectations. Readers are urged to
consider statements that include the words may, will, would, could, should, might, believes, estimates, projects, potential,
expects, plans, anticipates, intends, continues, forecast, designed, goal, unaudited, approximately or the negative of those
words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risks and uncertainties, without
limitation, associated with the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and
uncertainties described under the heading Risk Factors in the companys Annual Report on Form 10-K for the year ended December 31, 2014 filed with Securities and Exchange Commission on March 26, 2015. Although the company
believes that the expectations reflected in these forward-looking statements are reasonable, it cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements
will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.
Zosano Contact:
Vikram Lamba
Chief Executive Officer
510-745-1200
Investor Contact:
Paul Chun
Westwicke Partners
858-356-5931
paul.chun@westwicke.com
Media Contact:
Jamie Lacey-Moreira
PressComm PR, LLC
410-299-3310
jamielacey@presscommpr.com
###
ZOSANO PHARMA CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited; in thousands, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
2015 |
|
|
2014 |
|
Revenue: |
|
|
|
|
|
|
|
|
License fees revenue |
|
$ |
102 |
|
|
$ |
1,375 |
|
Collaborative development support services |
|
|
116 |
|
|
|
226 |
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
|
218 |
|
|
|
1,601 |
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
Cost of license fees revenue |
|
|
|
|
|
|
100 |
|
Research and development |
|
|
3,070 |
|
|
|
2,885 |
|
General and administrative |
|
|
1,299 |
|
|
|
1,184 |
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
4,369 |
|
|
|
4,169 |
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
|
(4,151 |
) |
|
|
(2,568 |
) |
Other income (expenses): |
|
|
|
|
|
|
|
|
Interest expense, net |
|
|
(492 |
) |
|
|
(301 |
) |
Other income |
|
|
12 |
|
|
|
|
|
Warrant revaluation income |
|
|
48 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss before gain on debt forgiveness |
|
|
(4,583 |
) |
|
|
(2,869 |
) |
Gain on debt forgiveness |
|
|
|
|
|
|
497 |
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(4,583 |
) |
|
$ |
(2,372 |
) |
|
|
|
|
|
|
|
|
|
Net loss per common share - basic and diluted |
|
$ |
(0.47 |
) |
|
$ |
(0.46 |
) |
|
|
|
|
|
|
|
|
|
Weighted-average shares used in computing net loss per common share - basic and diluted |
|
|
9,786 |
|
|
|
5,107 |
|
|
|
|
|
|
|
|
|
|
ZOSANO PHARMA CORPORATION AND SUBSIDIARIES
SELECTED CONSOLIDATED BALANCE SHEETS DATA
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
December 31, |
|
|
|
2015 |
|
|
2014 |
|
|
|
(unaudited) |
|
|
|
|
Cash and cash equivalents |
|
$ |
55,917 |
|
|
$ |
1,214 |
|
Total current assets |
|
|
56,792 |
|
|
|
1,636 |
|
Total assets |
|
|
66,429 |
|
|
|
13,343 |
|
Secured promissory notes, current |
|
|
1,457 |
|
|
|
1,408 |
|
Related parties convertible notes* |
|
|
|
|
|
|
7,362 |
|
Long-term debt |
|
|
13,223 |
|
|
|
13,291 |
|
Total liabilities |
|
|
16,901 |
|
|
|
26,744 |
|
Stockholders equity (deficit) |
|
|
49,528 |
|
|
|
(13,401 |
) |
* |
On January 30, 2015, upon the closing of the companys initial public offering of common stock, the principal and all unpaid and accrued interest on each convertible promissory note outstanding as of
January 30, 2015, which totaled $7.4 million, automatically converted into shares of common stock, resulting in the liability for such notes being reclassified to permanent equity. |
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024